title: Hematologic malignancies: where do we stand in 2011?
authors.affiliation: University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Charles
authors.initials: C
authors.lastname: Schiffer
authors.forename: Alan
authors.initials: A
authors.lastname: Burnett
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D047428:Protein Kinase Inhibitors; D000069283:Rituximab; D016044:Fusion Proteins, bcr-abl; D053614:Janus Kinase 2